and represents an exciting LRA candidate as it combines robust viral reactivation 60 potential with a low toxicity profile. At concentrations that blocked histone de-61 acetylation, panobinostat displayed a wide range of potency among participant samples 62 and consistently induced significant levels of apoptosis. The protein kinase C agonist 63 ingenol 3,20 dibenzoate demonstrates significant promise in a rapid ex vivo assay using 64 resting CD4 +
Introduction 68
Durable blockade of viral replication by combinations of antiretroviral drugs has 69 transformed HIV-1 infection from an untreatable, lethal condition characterized by 70 progressive immune deficiency into a chronic, manageable medical problem for the vast 71 majority of patients with access to therapy(1). Despite the ability of ART to block 72 ongoing HIV-1 replication and allow for restoration of the circulating CD4 + T cell 73 population, HIV-1 eradication does not occur with these drugs due to the presence of 74 long-lived viral reservoirs in resting memory CD4 + T cells(2-4). ART can continuously 75 suppress viral replication for years or even decades, however patients who stop 76 therapy will develop viremia within a matter of weeks and progress to overt 77 immunodeficiency if ART is not resumed(5). This rebound viremia arises from a 78 minority of cells among the resting memory CD4 + T cell population harboring 79 unexpressed HIV-1 proviral DNA that is stably integrated into the cellular genome(6). 80
81
The HIV-1 latent reservoir in patients on ART is stable over a period of many years, and 82 does not decay significantly during the lifespan of an infected patient(7). It is generally 83 accepted that eradication of the virus will require elimination of this latent reservoir (8, 84 9). The absence of specific markers to distinguish latently infected cells from uninfected 85 ones has led to the proposition that substances able to reverse the latent viral state 86 should be used to "purge" the latent reservoir(10). Infected cells could then potentially 87 be cleared via viral cytopathic effects or immune-mediated mechanisms (11) . 88 89 Real-time quantitative polymerase chain reaction Supernatant from each well is 135 collected for quantification of cell-free virions using a two-step quantitative polymerase 136 chain reaction (qPCR) that makes use of a primer and probe set for conserved regions 137 of the 3' LTR of HIV-1 mRNA using recently published methods (25) . 138
Culture supernatant undergoes DNase treatment (Quanta Biosciences) followed by 139 cDNA synthesis using qScript cDNA Supermix containing oligo-dT primers and random 140 hexamers according to manufacturer's protocol (Quanta Biosciences). RNA aliquots that 141 do not contain reverse transcriptase (no RT controls) were run in parallel for every 142 sample. Real-time quantitative PCR was subsequently performed in triplicate on cDNA 143
and RNA (no RT control) samples using TaqMan Universal Master Mix II (Applied 144 Biosystems) on a Roche LC480 Real-Time PCR instrument. Primers and probe used 145 were as follows: forward primer (5' to 3') CAGATGCTGCATATAAGCAGCTG, reverse 146 primer (5' to 3') TTTTTTTTTTTTTTTTTTTTTTTTGAAGCAC and probe (5' to 3') FAM-147 CCTGTACTGGGTCTCTCTGG-BHQ1. Cycling conditions were as follows: 50°C for two 148 minutes followed by 95°C for ten minutes for polymerase activation, followed by 45 149 cycles of 95°C for 15 seconds and 60°C for one minute. Serial ten-fold dilutions of a 150 plasmid containing the HIV-1 3'LTR (VQA plasmid; obtained from Greg Laird and 151 Robert Siliciano) from 10 6 to 10 0 copy per well were amplified in triplicate along with 152 unknowns in order to provide a standard curve and quantify cell-associated viral 153 mRNA. This assay has been shown to be highly specific for the detection of HIV-1 mRNA 154 with a lower limit of detection of 50 HIV-1 mRNA copies/mL(25). 155
Biomarker flow cytometry After 48 hours in culture, aliquots of 10 5 cells are fixed using 157 BD Cytofix TM Fixation Buffer (50% by volume; BD Biosciences) for 10 minutes at 37°C. 158
After incubation, DMSO (Fisher Scientific) was added to the sample to a final 159 concentration of 10% and frozen at -80°C. At the time of analysis, samples were thawed 160 on ice and re-suspended in 2 mL of phosphate-buffered saline (PBS 
Results
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Participants We recruited 12 HIV-1 positive, aviremic participants on ART (participant 187 characteristics shown in Table 1 ). Two participants, H025 and H026, returned for a 188 second phlebotomy during the study period. We therefore report the results of fourteen 189 independent ex vivo experiments using resting CD4 + T cells (rCD4) Viral release in the absence of stimulation (culture medium plus DMSO) was only 220 detected in two aliquots and at very low levels (geometric mean 52 copies/mL, range 221 14-96 copies/mL; Figure 1 ). The ratio of means between our positive and negative 222 control was 74.1 (range 11.4 -481.3 with a probability of difference P<0.0001) 223
representing the average fold increase in viral RNA copies detected between these 224 conditions. Low level viral release in negative control samples may reflect sub-optimal 225 ART compliance or viral 'blips' at the time of phlebotomy(27). Supernatant from the 226 HIV-1-uninfected donor did not demonstrate any detectable viral mRNA from any 227 condition. Viral release from rCD4 T cells exposed to CD3/CD28 antibodies was 228 accompanied by induction of CD69 and a modest increase in histone acetylation 229 measured by flow cytometry (Figures 2 and 3, respectively) . We designed the REVEAL assay to amplify genomic RNA from virions in the culture 243 supernatant. It has long been recognized that virions will pellet out of supernatant 244 when subjected to ultracentrifugation while naked mRNA will not(31). To verify that 245 detected RNA was pelletable, supernatants the CD3/CD28 condition of one donor was 246 subjected to ultracentrifugation followed by qPCR. Initial REVEAL analysis in 247 unconcentrated supernatant measured a total of 1500 mRNA copies. The authors are grateful to our study participants for their willingness to take part in 438 ongoing translational research including the experiments described in this manuscript. 439
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